Edgewise Therapeutics (EWTX) CMO grants, RSU exercises and 9,441-share sale
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. CMO Joanne M. Donovan reported multiple equity transactions. On August 12, 2026, she exercised 12,812 Restricted Stock Units into common stock at $0.00 per share and received new awards of 32,500 RSUs and 65,000 stock options, each for no additional cash consideration. The options cover 65,000 shares of common stock and vest in 48 equal monthly installments beginning September 12, 2026. On August 12–13, 2026, she sold a total of 9,441 shares of common stock at average prices between $43.12 and $44.57 per share. Footnotes state that 2026-08-12 sales were executed as "sell-to-cover" transactions to satisfy statutory tax withholding on RSU vesting, and the August 13 sale of 2,919 shares was made under a pre-arranged Rule 10b5-1 Plan adopted on December 26, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
11 txns
Insider
Donovan Joanne M.
Role
CMO
Sold
9,441 shs ($413K)
Approx. gross sale proceeds
$413K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F7, F8 | 2,919 | $43.4065 | $127K |
| Exercise | Restricted Stock Units F9 | 5,781 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F10 | 7,031 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F11 | 32,500 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F12 | 65,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 5,781 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,031 | $0.00 | $0.00 |
| Sale | Common Stock F2, F3 | 2,839 | $43.784 | $124K |
| Sale | Common Stock F2, F4 | 2,779 | $43.7073 | $121K |
| Sale | Common Stock F2, F5 | 104 | $44.4253 | $5K |
| Sale | Common Stock F2, F6 | 800 | $44.5175 | $36K |
Holdings After Transaction:
Restricted Stock Units — 65,157 shares (Direct);
Stock Option (Right to Buy) — 65,000 shares (Direct);
Common Stock — 8,625 shares (Direct)
Footnotes (12)
- F1. Includes 887 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
- F10. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
- F11. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
- F12. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
- F2. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
- F3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.23 to $44.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.42 to $44.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $44.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7. The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
- F8. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F9. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
Key Figures
Total shares sold: 9,441 shares
Sale price range: $43.12–$44.57 per share
RSUs exercised: 12,812 shares
+3 more
6 metrics
Total shares sold
9,441 shares
Aggregate common stock sales on August 12–13, 2026 by the CMO
Sale price range
$43.12–$44.57 per share
Weighted-average price ranges for reported common stock sales
RSUs exercised
12,812 shares
Restricted Stock Units converted into common stock on August 12, 2026
New RSU grant
32,500 units
RSUs granted August 12, 2026, vesting in four equal annual installments
New stock option grant
65,000 shares at $0.0000
Options granted August 12, 2026, vesting 1/48 monthly from September 12, 2026
10b5-1 plan adoption date
December 26, 2025
Rule 10b5-1 Plan governing the August 13, 2026 sale of 2,919 shares
Key Terms
Restricted Stock Units, Rule 10b5-1 Plan, sell-to-cover, statutory tax withholding obligations, +1 more
5 terms
Restricted Stock Units financial
"Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 Plan regulatory
"The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
sell-to-cover financial
"to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale"
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
statutory tax withholding obligations financial
"shares sold to cover the statutory tax withholding obligations in connection with the vesting of RSUs"
vest financial
"1/48th of the shares subject to the option vest each month beginning on September 12, 2026"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What did Edgewise Therapeutics (EWTX) CMO Joanne Donovan report in this Form 4?
Joanne Donovan reported exercising 12,812 RSUs into common stock, receiving new awards of 32,500 RSUs and 65,000 stock options, and selling 9,441 shares of Edgewise Therapeutics common stock in August 2026.
Were Joanne Donovan’s Edgewise Therapeutics (EWTX) stock sales discretionary?
Footnotes state that August 12, 2026 sales were sell-to-cover trades to satisfy statutory tax withholding on RSU vesting, and the August 13, 2026 sale of 2,919 shares was effected under a pre-arranged Rule 10b5-1 Plan adopted December 26, 2025.
What new equity awards did the Edgewise Therapeutics (EWTX) CMO receive?
On August 12, 2026, the CMO received 32,500 RSUs and 65,000 stock options, each granted for no additional cash consideration. The RSUs vest annually over four years, and the options vest monthly over 48 months starting September 12, 2026.
How do the RSU exercises affect Edgewise Therapeutics (EWTX) CMO’s holdings?
The CMO exercised 12,812 RSUs into an equal number of common shares at $0.00 per share on August 12, 2026. Resulting total holdings are not provided in this report, but she simultaneously received additional RSU and option grants for future vesting.
What is the vesting schedule of the new Edgewise Therapeutics (EWTX) stock options?
Footnotes state that 1/48th of the 65,000-share stock option vests each month beginning September 12, 2026, conditioned on the CMO’s continued service as a provider through each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
